Publication:
How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?

Simple item page
dc.contributor.authorsOglu, Gulcebi Idriz M.; Ozkaynakci, A.; Goren, M. Z.; Ozkara, C.; Gulhan, R.; Onat, F.
dc.date.accessioned2022-03-12T16:13:43Z
dc.date.accessioned2026-01-10T19:13:27Z
dc.date.available2022-03-12T16:13:43Z
dc.date.issued2011
dc.identifier.doidoiWOS:000292761500217
dc.identifier.issn0163-4356
dc.identifier.urihttps://hdl.handle.net/11424/225033
dc.identifier.wosWOS:000292761500217
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofTHERAPEUTIC DRUG MONITORING
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectallele
dc.subjectantiepileptic drug
dc.subjectlamotrigine
dc.subjectmetabolism
dc.subjectpharmacogenetics
dc.subjecttherapeutic drug monitoring
dc.titleHow is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage521
oaire.citation.issue4
oaire.citation.startPage521
oaire.citation.titleTHERAPEUTIC DRUG MONITORING
oaire.citation.volume33

Files

Collections

Araştırma Çıktıları